NASDAQ:IOBT IO Biotech (IOBT) Stock Forecast, Price & News $2.00 -0.02 (-0.99%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$1.96▼$2.0350-Day Range$1.80▼$2.1552-Week Range$1.72▼$5.76Volume7,374 shsAverage Volume52,448 shsMarket Capitalization$57.77 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media IO Biotech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside448.6% Upside$11.00 Price TargetShort InterestBearish1.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.83Based on 2 Articles This WeekInsider TradingAcquiring Shares$58,000 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.74) to ($2.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector683rd out of 986 stocksPharmaceutical Preparations Industry331st out of 483 stocks 3.5 Analyst's Opinion Consensus RatingIO Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, IO Biotech has a forecasted upside of 448.6% from its current price of $2.01.Amount of Analyst CoverageIO Biotech has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted1.71% of the float of IO Biotech has been sold short.Short Interest Ratio / Days to CoverIO Biotech has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldIO Biotech does not currently pay a dividend.Dividend GrowthIO Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IOBT. Previous Next 0.7 News and Social Media Coverage News SentimentIO Biotech has a news sentiment score of -0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for IO Biotech this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for IOBT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IO Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $58,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of IO Biotech is held by insiders.Percentage Held by Institutions53.23% of the stock of IO Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for IO Biotech are expected to grow in the coming year, from ($2.74) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IO Biotech is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IO Biotech is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIO Biotech has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IO Biotech (NASDAQ:IOBT) StockIO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Read More Receive IOBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IO Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address IOBT Stock News HeadlinesJune 5, 2023 | americanbankingnews.comAnalyzing IO Biotech (IOBT) and The CompetitionJune 1, 2023 | finance.yahoo.comIO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program LeadJune 6, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 25, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on IO Biotech (IOBT)May 15, 2023 | americanbankingnews.comIO Biotech (NASDAQ:IOBT) Price Target Raised to $11.00May 13, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on IO Biotech (IOBT)May 11, 2023 | seekingalpha.comIO Biotech GAAP EPS of -$0.59 beats by $0.09May 11, 2023 | finance.yahoo.comIO Biotech Announces 2023 First-Quarter ResultsJune 6, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 11, 2023 | americanbankingnews.comIO Biotech (IOBT) vs. Its Competitors Head-To-Head SurveyMay 2, 2023 | finance.yahoo.comIs IO Biotech (NASDAQ:IOBT) In A Good Position To Invest In Growth?March 25, 2023 | americanbankingnews.comIO Biotech, Inc. (NASDAQ:IOBT) to Post Q1 2023 Earnings of ($0.68) Per Share, Jefferies Financial Group ForecastsMarch 24, 2023 | americanbankingnews.comIO Biotech, Inc. (NASDAQ:IOBT) Forecasted to Post Q4 2023 Earnings of ($0.68) Per ShareMarch 23, 2023 | americanbankingnews.comInsider Buying: IO Biotech, Inc. (NASDAQ:IOBT) CFO Buys $58,000.00 in StockMarch 22, 2023 | finance.yahoo.comThe Chief Financial Officer of IO Biotech, Inc. (NASDAQ:IOBT), Amy Sullivan, Just Bought A Few More SharesMarch 17, 2023 | benzinga.comIO Biotech Stock (NASDAQ:IOBT), Short Interest ReportMarch 14, 2023 | finance.yahoo.comIO Biotech Announces 2022 Fourth-Quarter and Year-End ResultsFebruary 24, 2023 | barrons.comIO Biotech Inc.February 22, 2023 | finance.yahoo.comIO Biotech to Participate in March 2023 Investor ConferencesJanuary 24, 2023 | markets.businessinsider.comMorgan Stanley Reaffirms Their Buy Rating on IO Biotech (IOBT)January 23, 2023 | finance.yahoo.comIO Biotech Announces Appointment of Devin Smith as General CounselJanuary 9, 2023 | finance.yahoo.comIO Biotech Provides Business UpdateNovember 21, 2022 | finance.yahoo.comAnalyst Says IO Biotech's Cancer Treatment Approach 'Differentiated'November 9, 2022 | finance.yahoo.comIO Biotech Announces Third Quarter Results for 2022November 9, 2022 | finance.yahoo.comIO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual MeetingNovember 3, 2022 | finance.yahoo.comIO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable TumorsOctober 31, 2022 | finance.yahoo.comIO Biotech to Participate in the Jefferies London Healthcare ConferenceSee More Headlines IOBT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IOBT Company Calendar Last Earnings3/14/2023Today6/05/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IOBT CUSIPN/A CIK1865494 Webwww.iobiotech.com Phone45-7070-2980FaxN/AEmployees19Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+447.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-48.61% Return on Assets-45.18% Debt Debt-to-Equity RatioN/A Current Ratio12.77 Quick Ratio12.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.82 per share Price / Book0.42Miscellaneous Outstanding Shares28,815,000Free Float27,806,000Market Cap$57.92 million OptionableNot Optionable Beta-0.69 Key ExecutivesDr. Mai-Britt Zocca Ph.D. (Age 55)Founder, Pres, CEO, Principal Financial Officer & Director Comp: $514.12kDr. Muhammad Al-Hajj Ph.D. (Age 51)Chief Scientific Officer Comp: $486.63kDr. Eva Ehrnrooth M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $443.5kProf. Inge Marie Svane M.D.Ph.D., Founder & Clinical AdvisorProf. Mads Hald Andersen Ph.D.Founder & Scientific AdvisorAnders LjungqvistFounderProf. Per Thor StratenFounderMs. Amy B. SullivanChief Financial OfficerMr. Brian Burkavage (Age 39)VP of Fin. & Chief Accounting Officer Mr. Mikkel Dybkjær (Age 50)VP of Corp. Fin. More ExecutivesKey CompetitorsLantern PharmaNASDAQ:LTRNGalectoNASDAQ:GLTOLifeVantageNASDAQ:LFVNConnect BiopharmaNASDAQ:CNTBAbeona TherapeuticsNASDAQ:ABEOView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCBought 37,500 shares on 5/12/2023Ownership: 0.214%Amy SullivanBought 25,000 shares on 3/17/2023Total: $58,000.00 ($2.32/share)View All Insider TransactionsView All Institutional Transactions IOBT Stock - Frequently Asked Questions Should I buy or sell IO Biotech stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IO Biotech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IOBT shares. View IOBT analyst ratings or view top-rated stocks. What is IO Biotech's stock price forecast for 2023? 2 equities research analysts have issued 12-month target prices for IO Biotech's shares. Their IOBT share price forecasts range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 447.3% from the stock's current price. View analysts price targets for IOBT or view top-rated stocks among Wall Street analysts. How have IOBT shares performed in 2023? IO Biotech's stock was trading at $2.30 at the beginning of 2023. Since then, IOBT stock has decreased by 12.6% and is now trading at $2.01. View the best growth stocks for 2023 here. When is IO Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our IOBT earnings forecast. How were IO Biotech's earnings last quarter? IO Biotech, Inc. (NASDAQ:IOBT) announced its quarterly earnings results on Tuesday, March, 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.12. When did IO Biotech IPO? (IOBT) raised $111 million in an initial public offering on Friday, November 5th 2021. The company issued 7,150,000 shares at a price of $14.00-$17.00 per share. What is IO Biotech's stock symbol? IO Biotech trades on the NASDAQ under the ticker symbol "IOBT." Who are IO Biotech's major shareholders? IO Biotech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.21%). View institutional ownership trends. How do I buy shares of IO Biotech? Shares of IOBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IO Biotech's stock price today? One share of IOBT stock can currently be purchased for approximately $2.01. How much money does IO Biotech make? IO Biotech (NASDAQ:IOBT) has a market capitalization of $57.92 million. The company earns $-71,460,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. How can I contact IO Biotech? The official website for the company is www.iobiotech.com. The company can be reached via phone at 45-7070-2980. This page (NASDAQ:IOBT) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.